TACSTD2 and prostate neoplasm: Based on these findings we propose that high TROP2 expression identifies TIC sub-populations with different phenotypes in androgen-sensitive and androgen-independent prostate tumors and that it may represent a worthwhile predictive biomarker for prostate cancer treatment response in androgen-sensitive tumors.